Compare TRIB & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | ACON |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 7.4M |
| IPO Year | 1996 | 2022 |
| Metric | TRIB | ACON |
|---|---|---|
| Price | $7.47 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 21.7K | ★ 59.9K |
| Earning Date | 05-22-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,730.00 |
| Revenue This Year | $13.51 | $87.22 |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.62 |
| 52 Week Low | $0.28 | $1.95 |
| 52 Week High | $14.17 | $12.03 |
| Indicator | TRIB | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | N/A |
| Support Level | $0.55 | N/A |
| Resistance Level | $14.03 | N/A |
| Average True Range (ATR) | 0.72 | 0.00 |
| MACD | -0.51 | 0.00 |
| Stochastic Oscillator | 10.90 | 0.00 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.